Rekvina Laboratories Financial Statements
Rekvina Laboratories financial statements. In FYNone, Rekvina Laboratories (VINRKLB) reported revenue ₹2 Cr, net profit ₹0 Cr and EPS ₹-0.50. Full financial statements from FY2015 to FY2026 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Read VINRKLB ex-dividend dates for the complete payout history and dividend yield track record.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
VINRKLB Revenue, Net Profit & EBITDA — Year-on-Year Growth
VINRKLB YoY (March 2026 vs Period) — revenue +100.0%. Analyse VINRKLB shareholder distribution to track promoter, FII and institutional holdings.
VINRKLB Income Statement — Revenue, EBITDA & Net Profit
Rekvina Laboratories revenue ₹2 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹-0.50 (None). For live price, earnings ratios and company overview, see VINRKLB screener.
| Particulars | None | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Profit Margin % | -19.00% | -20.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -90.00% | 15.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Earnings Per Share (₹) | -0.50 | -0.42 | -0.23 | -0.03 | 0.00 | -0.13 | -0.11 | 0.00 | -0.13 | -0.03 | -0.09 | 0.01 |
VINRKLB Balance Sheet — Assets, Liabilities & Shareholders' Equity
VINRKLB total assets ₹1 Cr, total equity ₹-1 Cr, total liabilities ₹ Cr (2026).
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Current Assets | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 4,583 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1 | 0 | 0 | -4,583 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| LIABILITIES | |||||||||||
| Total Liabilities | |||||||||||
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Share Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves & Surplus | -4 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 |
VINRKLB Cash Flow Statement — Operating, Investing & Financing
Rekvina Laboratories operating cash flow ₹-1 Cr, investing ₹0 Cr, financing ₹1 Cr, net cash flow ₹0 Cr (2026).
| Particulars | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Activities | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |